Induction of fetal hemoglobin in the treatment of sickle cell disease and β thalassemia

Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Second Edition

Volumn , Issue , 2009, Pages 745-754

  Saunthararajah, Yogen ^a   Atweh, George F ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955894072     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511596582.041     Document Type: Chapter

References (83)

1. Watson J. The significance of the paucity of sickle cells in newborn negro infants. Am JMed Sci. 1948;215:419-423.
2. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann InternMed. 1978;88(1):1-6.
3. Brittenham G, Lozoff B, Harris JW, Mayson SM, Miller A, Huisman TH. Sickle cell anemia and trait in southern India: further studies. Am J Hematol. 1979;6(2):107-123.
4. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11-16.
5. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death.NEngl J Med. 1994;330(23):1639-1644.
6. Poillon WN, Kim BC, Rodgers GP, Noguchi CT, Schechter AN. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci USA. 1993;90(11):5039-5043.
7. Mavilio F, Giampaolo A, Care A, et al. Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal, and adult erythroblasts.Proc Natl Acad SciUSA. 1983;80(22):6907-6911.
8. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85-93.
9. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood. 2000;96(7):2379-2384.
10. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2ʹ-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA. 1994;91(25):11797-11801.
11. Heller P, DeSimone J. 5-Azacytidine and fetal hemoglobin. Am J Hematol. 1984;17(4):439-447.
12. Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.NEngl J Med. 1982;307(24):1469-1475.
13. Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood. 1983;62(2):370-380.
14. Charache S, Dover G, Smith K, Talbot CC Jr, Moyer M, Boyer S. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gammadelta-beta-globin gene complex. Proc Natl Acad Sci USA. 1983;80(15):4842-4846.
15. Humphries RK, Dover G, Young NS, et al. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J Clin Invest. 1985; 75(2):547-557.
16. Lowrey CH, Nienhuis AW. Brief report: treatment with azacitidine of patients with end-stage beta-thalassemia. N Engl J Med. 1993;329(12):845-848.
17. Carr BI, Reilly JG, Smith SS, Winberg C, Riggs A. The tumorigenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis. 1984;5(12):1583-1590.
18. Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer. 1988;57(4):395-402.
19. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of theMulticenter Study of Hydroxyurea in Sickle Cell Anemia. NEngl J Med. 1995;332(20):1317-1322.
20. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 2002;99(11):3905-3908.
21. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2ʹ-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102(12):3865-38670.
22. Milhem M, Mahmud N, Lavelle D, et al. Modification of hematopoietic stem cell fate by 5aza 2ʹdeoxycytidine and trichostatin A. Blood. 2004;103(11):4102-4110.
23. Atweh GF, DeSimone J, Saunthararajah Y, et al. Hemoglobinopathies. AmSoc Hematol Educ Program. 2003:14-39.
24. Rodgers GP, Saunthararajah Y. Advances in experimental treatment of beta-thalassaemia. Expert Opin Investig Drugs. 2001;10(5):925-934.
25. Saunthararajah Y, Molokie R, Saraf S, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol. 2008;141(1):126-129.
26. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. ExpHematol. 2005;33(3):259-271.
27. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med. 1984;310(14): 869-873.
28. Platt OS, Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656.
29. Rodgers GP, Steinberg MH. Pharmacologic treatment of sickle cell disease and thalassemia: the augmentation of fetal hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. 1st ed. Cambridge: Cambridge University Press; 2001:1028-1051.
30. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin.Medicine (Baltimore). 2001;80(5):328-344.
31. Hankins JS, Ware RE, Rogers ZR, et al. Long-termhydroxyurea therapy for infants with sickle cell anemia-the Husoft extension study. Blood. 2005;106:2269-2275.
32. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628-3632.
33. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyureainduced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood. 1987;69(1):109-116.
34. Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW.Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med. 1990;322(15): 1037-1045.
35. Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006;4:59-66.
36. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651.
37. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 2002;99(1):10-14.
38. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood. 2005;105(7):2685-2690.
39. WangWC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr. 2001;139(6):790-796.
40. WangWC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUGKIDS Study. J Pediatr. 2002;140(2):225-229.
41. de Montelembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P. Long-termhydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica. 2006;91(1):125-128.
42. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained longterm hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004; 103(6):2039-2045.
43. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 1999; 94(9):3022-3026.
44. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood. 2007; 110(3):1043-1047.
45. Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer. 2006; 47(7):894-900.
46. WangWC. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Curr Opin Hematol. 2007;14(3): 191-197.
47. Ware RE, Zimmerman SA, Sylvestre PB, et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr. 2004;145(3):346-352.
48. Miller MK, Zimmerman SA, Schultz WH, Ware RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol. 2001;23(5):306-308.
49. Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea inHb SC disease. Br J Haematol. 1997;98(4):838-844.
50. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2004;105:545-547.
51. Hanft VN, Fruchtman SR, Pickens CV, Rosse WF, Howard TA, Ware RE. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood. 2000; 95(11):3589-3593.
52. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7:386-394.
53. Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest. 2003;111(2): 231-239.
54. Saleh AW, Hillen HF, Duits AJ. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 1999; 102(1):31-37.
55. Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood. 1996;88(12):4701-4710.
56. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.Medicine (Baltimore). 1996;75(6):300-326.
57. Ginder GD, Whitters MJ, Pohlman JK. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc Natl Acad Sci USA. 1984;81(13):3954-3958.
58. Perrine SP, Greene MF, Faller DV. Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med. 1985; 312(6):334-338.
59. Bard H, Prosmanne J. Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. Pediatrics. 1985;75(6): 1143-1147.
60. Perrine SP, Rudolph A, Faller DV, et al. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci USA. 1988;85(22):8540-8542.
61. Constantoulakis P, Papayannopoulou T, Stamatoyannopoulos G. Alpha-amino-N-butyric acid stimulates fetal hemoglobin in the adult. Blood. 1988;72(6):1961-1967.
62. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the betaglobin disorders. NEngl J Med. 1993;328(2):81-86.
63. Sher GD, Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med. 1995;332(24):1606-1610.
64. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994;84(1):339-343.
65. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6):1790-1797.
66. Forsberg EC, Downs KM, Christensen HM, Im H, Nuzzi PA, Bresnick EH. Developmentally dynamic histone acetylation pattern of a tissue-specific chromatin domain. Proc Natl Acad Sci USA. 2000;97(26):14494-14499.
67. Heinzel T, Lavinsky RM, Mullen TM, et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 1997;387(6628):43-48.
68. Laherty CD, YangWM, Sun JM, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell. 1997;89(3):349-356.
69. Pace BS, Chen YR, Thompson A, Goodman SR. Butyrateinducible elements in the human gamma-globin promoter. Exp Hematol. 2000;28(3):283-293.
70. Pace BS, Qian XH, Sangerman J, et al. p38 MAP kinase activation mediates gamma-globin gene induction in erythroid progenitors. Exp Hematol. 2003;31(11):1089-1096.
71. Pace BS, Zein S. Understanding mechanisms of gammaglobin gene regulation to develop strategies for pharmacological fetal hemoglobin induction. Dev Dyn. 2006;235(7): 1727-1737.
72. Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood. 2005;105(4):1807-1809.
73. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol. 2001;38(4):367-373.
74. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380-385.
75. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, De Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102(4):1529-1530.
76. Fathallah H, Sutton M, Atweh GF. Pharmacological induction of fetal hemoglobin: Why haven't we been more successful in thalassemia? Ann NY Acad Sci. 2005;1054:228-237.
77. Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I. Reduction of the clinical severity of sickle cell/b-thalassemia with hydroxyurea: The experience of a single center in Greece. Blood Cells Mol Dis. 2000;26(5):453-466.
78. Singer ST, Kuypers FA, Olivieri NF, et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol. 2005;131(3):378-388.
79. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetalhemoglobin response to hydroxyurea in sickle cell disease. N Engl JMed. 1993;328(2):73-80.
80. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350(9076):491-492.
81. Al-Jam'a AH, Al-Dabbous IA. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia. Saudi Med J. 2002;23(3):277-281.
82. Atweh GF, Schechter AN. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol. 2001;8(2):123-130.
83. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. NEngl J Med. 1988;318(2):96-99.